Esomeprazole
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastroesophageal Reflux Disease (GERD)
Conditions
Gastroesophageal Reflux Disease (GERD)
Trial Timeline
Nov 1, 2003 → Oct 1, 2007
NCT ID
NCT00574925About Esomeprazole
Esomeprazole is a approved stage product being developed by AstraZeneca for Gastroesophageal Reflux Disease (GERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00574925. Target conditions include Gastroesophageal Reflux Disease (GERD).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01370538 | Phase 3 | Completed |
| NCT01370525 | Phase 3 | Completed |
| NCT00474019 | Phase 1 | Completed |
| NCT00427635 | Phase 3 | Completed |
| NCT00384592 | Approved | Completed |
| NCT00318968 | Approved | Completed |
| NCT00608712 | Approved | Completed |
| NCT00251979 | Phase 3 | Completed |
| NCT00392002 | Approved | Completed |
| NCT00242736 | Approved | Completed |
| NCT00291746 | Approved | Completed |
| NCT00206440 | Phase 3 | Terminated |
| NCT00243724 | Phase 3 | Completed |
| NCT00524251 | Pre-clinical | Completed |
| NCT00251966 | Phase 3 | Completed |
| NCT00251901 | Phase 3 | Completed |
| NCT00120315 | Approved | Completed |
| NCT00574925 | Approved | Completed |
| NCT00222131 | Phase 2 | Completed |
| NCT00318084 | Approved | Completed |
Competing Products
20 competing products in Gastroesophageal Reflux Disease (GERD)